Akari Therapeutics ADR (AKTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -19,791 | -10,008 | -17,748 | -17,424 | -17,082 |
| Depreciation Amortization | 14 | 4 | 4 | 4 | 9 |
| Accounts payable and accrued liabilities | 5,223 | -936 | N/A | N/A | -248 |
| Other Working Capital | 6,539 | -866 | 822 | -1,984 | -56 |
| Other Operating Activity | -4,537 | -4,626 | -4,582 | 557 | 426 |
| Operating Cash Flow | $-12,552 | $-16,432 | $-21,504 | $-18,847 | $-16,950 |
| Cash Flows From Investing Activities | |||||
| Other Investing Activity | 382 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | $382 | $N/A | $N/A | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 1,000 | N/A | N/A | N/A | N/A |
| Debt Repayment | -750 | N/A | N/A | N/A | N/A |
| Common Stock Issued | 11,817 | 7,020 | 25,288 | 14,293 | 25,074 |
| Other Financing Activity | -1,079 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | $10,988 | $7,020 | $25,288 | $14,293 | $25,074 |
| Exchange Rate Effect | -4 | 7 | 105 | -141 | 201 |
| Beginning Cash Position | 3,845 | 13,250 | 9,361 | 14,056 | 5,732 |
| End Cash Position | 2,659 | 3,845 | 13,250 | 9,361 | 14,056 |
| Net Cash Flow | $-1,186 | $-9,405 | $3,889 | $-4,695 | $8,324 |
| Free Cash Flow | |||||
| Operating Cash Flow | -12,552 | -16,432 | -21,504 | -18,847 | -16,950 |
| Free Cash Flow | -12,552 | -16,432 | -21,504 | -18,847 | -16,950 |